TARA,MDGL Stock Price and Quote

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.23
Percentage change -6.61	%

Peers: BMRN CRSP NTLA SRPT RARE QURE BLUE SGMO VYGR PGEN

| Held by: VTI VXF AVSC IWC DFAT DFAS DFAU DFAC DCOR DFSU

Index	-	P/E	-	EPS (ttm)	-1.73	Insider Own	10.58%	Shs Outstand	38.58M	Perf Week	3.83%
Market Cap	125.39M	Forward P/E	-	EPS next Y	-1.92	Insider Trans	-0.03%	Shs Float	34.50M	Perf Month	-17.51%
Income	-45.41M	PEG	-	EPS next Q	-0.43	Inst Own	69.41%	Short Float	7.18%	Perf Quarter	-17.72%
Sales	0.00M	P/S	-	EPS this Y	27.73%	Inst Trans	88.37%	Short Ratio	6.87	Perf Half Y	31.58%
Book/sh	4.11	P/B	0.79	EPS next Y	-22.68%	ROA	-38.37%	Short Interest	2.48M	Perf Year	5.18%
Cash/sh	3.22	P/C	1.01	EPS next 5Y	3.42%	ROE	-41.88%	52W Range	1.60 - 10.48	Perf YTD	-38.45%
Dividend Est.	-	P/FCF	-	EPS past 5Y	55.31%	ROI	-28.11%	52W High	-68.99%	Beta	1.38
Dividend TTM	-	Quick Ratio	18.03	Sales past 5Y	0.00%	Gross Margin	-	52W Low	103.76%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	18.03	EPS Y/Y TTM	53.83%	Oper. Margin	-	RSI (14)	41.66	Volatility	5.98% 7.90%
Employees	33	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.40
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	69.87%	Payout	-	Rel Volume	0.86	Prev Close	3.48
Sales Surprise	-	EPS Surprise	35.81%	Sales Q/Q	-	Earnings	May 08 BMO	Avg Volume	360.28K	Price	3.25
SMA20	-5.36%	SMA50	-16.64%	SMA200	-5.13%	Trades		Volume	309,023	Change	-6.61%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-25	Initiated	Scotiabank	Sector Outperform	$12
Mar-14-25	Initiated	Cantor Fitzgerald	Overweight
Jul-10-23	Resumed	Guggenheim	Buy	$22
Jun-04-21	Initiated	H.C. Wainwright	Buy	$40
Feb-17-21	Initiated	Oppenheimer	Outperform	$43
Oct-19-20	Initiated	Cowen	Outperform	$50
Jul-29-20	Initiated	Guggenheim	Buy	$50

May-13-25 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-08-25 08:00AM	Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-01-25 04:09PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-25 10:00AM	Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC (GlobeNewswire)
Apr-23-25 08:00AM	Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 (GlobeNewswire) +6.60%
04:13PM	Loading…
Apr-15-25 04:13PM	Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer (GlobeNewswire)
Apr-10-25 04:05PM	Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting (GlobeNewswire) -6.25%
Apr-09-25 12:00PM	Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.67%
Mar-28-25 05:10PM	Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results (Seeking Alpha) -6.99%
Mar-19-25 08:00AM	Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support (GlobeNewswire) +8.78%
Mar-05-25 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.04%
Feb-26-25 08:00AM	Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-05-25 08:00AM	Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-25 08:00AM	Protara Highlights Recent Updates and Anticipated 2025 Milestones (GlobeNewswire)
Jan-08-25 08:00AM	Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
04:05PM	Loading…
Dec-11-24 04:05PM	Protara Announces Closing of $100 Million Public Offering (GlobeNewswire)
Dec-09-24 11:35PM	Protara Announces Pricing of $100 Million Public Offering (GlobeNewswire) +12.86% -6.30%
04:01PM	Protara Announces Proposed Public Offering (GlobeNewswire)
Dec-05-24 07:00AM	Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC (GlobeNewswire) +70.06%
Dec-03-24 08:00AM	Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024 (GlobeNewswire) +11.46%
Nov-15-24 05:52PM	Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire) -6.48%
Nov-12-24 08:00AM	Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-06-24 08:00AM	Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire) -6.13%
Oct-21-24 08:00AM	Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support (GlobeNewswire) +5.24%
Sep-09-24 08:05AM	Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support (GlobeNewswire)
Sep-03-24 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-06-24 08:00AM	Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Jun-24-24 05:06PM	Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.83%
May-21-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
12:54PM	Loading…
May-02-24 12:54PM	TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-12-24 09:55AM	Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-05-24 08:04AM	Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing (GlobeNewswire) -9.70%
08:02AM	Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC (GlobeNewswire)
Mar-13-24 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -7.45%
Jan-31-24 07:30AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-30-23 08:30AM	Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-23 09:43AM	Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results (GuruFocus.com) +11.57%
08:00AM	Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-23-23 08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Sep-20-23 08:30AM	Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ (GlobeNewswire)
Sep-05-23 07:30AM	Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 08:00AM	Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-15-23 08:00AM	Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ (GlobeNewswire)
May-04-23 08:00AM	Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 08:00AM	Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Apr-28-23 08:00AM	Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development (GlobeNewswire)
Mar-08-23 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-23 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.76%
Feb-02-23 08:00AM	Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-30-23 08:00AM	Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer (GlobeNewswire)
Dec-01-22 08:00AM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-22 08:00AM	Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Oct-24-22 08:35AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-06-22 08:00AM	Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 08:00AM	Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Jun-21-22 08:00AM	Protara Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire)
May-26-22 05:11PM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +5.44%
May-17-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:32AM	Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely? (Simply Wall St.)
May-12-22 08:00AM	Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations (GlobeNewswire)
May-05-22 08:00AM	Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Apr-11-22 09:55AM	Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect? (Zacks) -6.17%
Mar-24-22 08:00AM	Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Mar-23-22 10:00AM	Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect? (Zacks) +5.06%
Mar-09-22 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview (GlobeNewswire)
Mar-08-22 05:50AM	Protara Therapeutics, Inc. (NASDAQ:TARA) insider upped their holding by 222% earlier this year (Simply Wall St.)
Mar-02-22 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.67%
Feb-01-22 08:00AM	Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference (GlobeNewswire) +8.25%
Jan-10-22 08:00AM	Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer (GlobeNewswire)
Jan-04-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-08-21 11:15AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-04-21 08:00AM	Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Oct-25-21 04:45PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-21 07:00AM	Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +11.85%
Sep-17-21 04:05PM	Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire)
Sep-13-21 07:00AM	Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
Sep-09-21 10:31AM	A number of insiders bought Protara Therapeutics, Inc. (NASDAQ:TARA) stock last year, which is great news for shareholders (Simply Wall St.)
Sep-07-21 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-05-21 08:00AM	Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Jul-07-21 08:00AM	Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Jun-22-21 07:30AM	ProBility Media Provides Corporate Update (PR Newswire)
Jun-10-21 08:00AM	Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors (GlobeNewswire)
May-13-21 08:00AM	Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences (GlobeNewswire)
May-06-21 07:30AM	Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview (GlobeNewswire) -5.69%
Apr-23-21 07:00AM	Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) -18.41%
Apr-19-21 04:09PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-12-21 11:12AM	The Dip in These 3 Stocks Is a Buying Opportunity, Say Analysts (TipRanks)
Mar-30-21 07:01AM	Do Insiders Own Lots Of Shares In Protara Therapeutics, Inc. (NASDAQ:TARA)? (Simply Wall St.)
Mar-11-21 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview (GlobeNewswire) +6.40%
Mar-10-21 08:00AM	Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire)
Feb-04-21 08:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Feb-02-21 08:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors (GlobeNewswire)
Dec-16-20 11:07PM	Is TARA A Good Stock To Buy Now? (Insider Monkey)
Dec-07-20 04:30PM	Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer (GlobeNewswire)

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levy Richard S	Director	May 14 '25	Buy	3.19	20,000	63,800	51,000	May 16 04:05 PM
Zummo Jacqueline	Chf Scientific Operations Off	Mar 26 '25	Sale	4.53	21,224	96,145	98,861	Mar 28 04:12 PM
Zummo Jacqueline	Officer	Mar 26 '25	Proposed Sale	4.55	21,224	96,569		Mar 26 11:17 AM
Opaleye Management Inc.	10% Owner	Sep 12 '24	Sale	1.71	126,301	215,836	45,000	Sep 12 08:20 PM
Opaleye Management Inc.	10% Owner	Sep 11 '24	Sale	1.71	32,600	55,880	51,500	Sep 12 08:20 PM
Opaleye Management Inc.	10% Owner	Sep 09 '24	Sale	1.89	36,492	69,141	54,600	Sep 10 07:11 PM
Opaleye Management Inc.	10% Owner	Sep 10 '24	Sale	1.77	25,500	45,110	53,100	Sep 10 07:11 PM
Opaleye Management Inc.	10% Owner	Jul 16 '24	Sale	2.44	11,396	27,828	56,500	Jul 18 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 11 '24	Sale	2.40	47,993	115,346	60,000	Jul 11 07:56 PM
Opaleye Management Inc.	10% Owner	Jul 10 '24	Sale	2.31	18,061	41,685	75,000	Jul 11 07:56 PM
Opaleye Management Inc.	10% Owner	Jul 09 '24	Sale	2.21	8,497	18,811	80,000	Jul 11 07:56 PM
Opaleye Management Inc.	10% Owner	Jul 01 '24	Sale	2.12	8,288	17,598	87,500	Jul 03 02:00 PM
Opaleye Management Inc.	10% Owner	Jun 27 '24	Sale	2.26	46,574	105,169	90,000	Jun 28 06:45 PM
Opaleye Management Inc.	10% Owner	Jun 28 '24	Sale	2.07	17,994	37,334	85,000	Jun 28 06:45 PM
Opaleye Management Inc.	10% Owner	Jun 25 '24	Sale	2.26	12,725	28,734	102,471	Jun 27 04:05 PM
Opaleye Management Inc.	10% Owner	May 30 '24	Sale	2.94	9,230	27,113	114,520	May 31 04:05 PM
Opaleye Management Inc.	10% Owner	May 31 '24	Sale	2.90	5,824	16,895	108,696	May 31 04:05 PM
Opaleye Management Inc.	10% Owner	May 22 '24	Sale	3.02	9,800	29,596	123,750	May 23 07:01 PM

Dollar change -15.52
Percentage change -5.30	%

MDGL Madrigal Pharmaceuticals Inc daily Stock Chart

Peers: GILD AKRO VKTX NBIX ENTA SLDB LXRX TSHA IMAB RDHL

| Held by: VTI VB IWM XBI VBR VXF IWO IBB VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-18.04	Insider Own	9.52%	Shs Outstand	22.19M	Perf Week	-1.99%
Market Cap	6.16B	Forward P/E	-	EPS next Y	-0.31	Insider Trans	-3.80%	Shs Float	20.09M	Perf Month	-8.42%
Income	-391.59M	PEG	-	EPS next Q	-3.49	Inst Own	107.12%	Short Float	20.43%	Perf Quarter	-21.02%
Sales	317.38M	P/S	19.40	EPS this Y	41.75%	Inst Trans	-4.47%	Short Ratio	11.02	Perf Half Y	-3.93%
Book/sh	32.03	P/B	8.66	EPS next Y	97.55%	ROA	-37.67%	Short Interest	4.10M	Perf Year	25.98%
Cash/sh	38.20	P/C	7.26	EPS next 5Y	-	ROE	-50.16%	52W Range	200.63 - 377.46	Perf YTD	-10.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-32.06%	ROI	-47.21%	52W High	-26.55%	Beta	-1.07
Dividend TTM	-	Quick Ratio	5.58	Sales past 5Y	0.00%	Gross Margin	96.20%	52W Low	38.18%	ATR (14)	15.80
Dividend Ex-Date	-	Current Ratio	5.91	EPS Y/Y TTM	21.83%	Oper. Margin	-133.95%	RSI (14)	35.38	Volatility	4.26% 5.28%
Employees	528	Debt/Eq	0.17	Sales Y/Y TTM	-	Profit Margin	-123.38%	Recom	1.29	Target Price	419.69
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	55.06%	Payout	-	Rel Volume	1.43	Prev Close	292.76
Sales Surprise	19.70%	EPS Surprise	11.43%	Sales Q/Q	-	Earnings	May 01 BMO	Avg Volume	372.50K	Price	277.24
SMA20	-9.29%	SMA50	-12.49%	SMA200	-5.17%	Trades		Volume	532,136	Change	-5.30%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Upgrade	B. Riley Securities	Neutral → Buy	$236 → $422
Feb-27-25	Reiterated	H.C. Wainwright	Buy	$400 → $405
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform	$382
Apr-22-24	Initiated	BofA Securities	Underperform	$150
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral	$155 → $270
Mar-06-24	Initiated	Citigroup	Buy	$382
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell	$155
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-22	Reiterated	Piper Sandler	Overweight	$203 → $280
Dec-19-22	Reiterated	H.C. Wainwright	Buy	$170 → $225
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral	$131 → $75
Oct-07-21	Initiated	Jefferies	Buy	$151
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy	$195
Nov-24-20	Resumed	Evercore ISI	Outperform	$180
Nov-06-20	Reiterated	H.C. Wainwright	Buy	$165 → $184
Jul-31-20	Initiated	Piper Sandler	Overweight	$208
Jun-05-20	Initiated	BMO Capital Markets	Market Perform	$135

Show Previous Ratings

May-15-25 07:21PM	John Paulson's Strategic Move: Honeywell International Inc. Takes Center Stage (GuruFocus.com)
May-13-25 09:45AM	2 Monster Stocks in the Making to Buy Now and Hold for 10 Years (Motley Fool)
May-10-25 07:15AM	Madrigal Announces New Clinical Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
May-08-25 11:41PM	Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker's Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 08:47AM	Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson's Stocks with Huge Upside Potential (Insider Monkey)
03:02AM	Loading…
May-02-25 03:02AM	Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
May-01-25 10:57PM	Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:01PM	Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript (Seeking Alpha)
10:40AM	Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
08:20AM	Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:17AM	Madrigal: Q1 Earnings Snapshot (Associated Press Finance)
07:17AM	Madrigals MASH drug sales again top Wall Street projections (BioPharma Dive)
07:00AM	Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-29-25 08:00AM	Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress (GlobeNewswire)
Apr-18-25 08:00AM	Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 (GlobeNewswire)
04:46AM	Loading…
04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 10:28AM	89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development (Seeking Alpha)
Apr-16-25 07:00AM	Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer (GlobeNewswire)
Apr-15-25 02:37PM	Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (Seeking Alpha)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha)
Mar-28-25 06:54PM	Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March? (Insider Monkey)
11:30AM	Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-21-25 08:30AM	Artisan International Small-Mid Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 10:34PM	Tracking John Paulson's Paulson & Co. Portfolio - Q4 2024 Update (SeekingAlpha)
Mar-18-25 05:28AM	Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-11-25 08:00AM	Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors (GlobeNewswire)
Mar-07-25 05:35AM	Goldman Sachs Says Its Time to Pull the Trigger on Healthcare Stocks Here Are 2 Names to Pounce on Now (TipRanks)
Feb-28-25 10:20AM	Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA (TipRanks)
Feb-27-25 02:05AM	Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) -5.66%
Feb-26-25 11:43PM	Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +14.99%
12:28PM	Loading…
12:28PM	Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis (Benzinga)
11:27AM	Why Madrigal Pharmaceuticals Stock Is Soaring Today (Motley Fool)
07:21AM	Madrigal: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
06:30AM	Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
Feb-21-25 08:00AM	Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-12-25 08:00AM	Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 (GlobeNewswire)
Jan-17-25 08:28AM	Why Madrigal Pharmaceuticals Stock Was Plummeting This Week (Motley Fool) +7.64%
Jan-13-25 11:20AM	Why Madrigal Pharmaceuticals Stock Is Sinking Today (Motley Fool) -10.39%
06:45AM	Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra (GlobeNewswire)
Jan-03-25 08:00AM	Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-06-24 06:46AM	Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities (TipRanks)
Nov-23-24 07:46AM	3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move (Motley Fool)
Nov-22-24 09:55AM	Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) +5.53%
Nov-21-24 05:12PM	Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-18-24 02:53AM	The first MASH drug could open the door for others including GLP-1s (Pharma Voice) +5.17%
Nov-14-24 09:12PM	John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC (GuruFocus.com)
Nov-10-24 09:30AM	1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More (Motley Fool)
Nov-06-24 08:00AM	Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 09:55AM	Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations (GuruFocus.com)
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:17PM	Madrigal Pharmaceuticals stock jumps on MASH drug hopes (Yahoo Finance Video) +23.23%
04:08PM	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH (Investor's Business Daily)
03:03AM	Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ... (GuruFocus.com)
Oct-31-24 07:28AM	Madrigal: Q3 Earnings Snapshot (Associated Press Finance) +20.10%
07:00AM	Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Oct-30-24 08:00AM	Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting (GlobeNewswire)
Oct-22-24 06:53AM	Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug (Clinical Trials Arena)
Oct-21-24 08:00AM	Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis (GlobeNewswire)
Oct-18-24 08:00AM	Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 (GlobeNewswire)
Oct-16-24 08:44AM	Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra (Insider Monkey)
Oct-02-24 08:00AM	Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference (GlobeNewswire)
Oct-01-24 08:00AM	Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development (GlobeNewswire)
Sep-30-24 08:00AM	Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra (resmetirom) (GlobeNewswire)
Sep-25-24 12:03AM	Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now? (Insider Monkey)
Aug-26-24 08:00AM	Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-17-24 10:15AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
Aug-14-24 11:55PM	John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc (GuruFocus.com)
06:00AM	This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock (Motley Fool)
Aug-13-24 11:33AM	Madrigal plans to solidify Rezdiffras position in MASH despite start being slower than expected (Pharmaceutical Technology)
Aug-08-24 03:47AM	Q2 2024 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily) -12.18%
11:12AM	Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line (Zacks)
07:20AM	Madrigal: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:30AM	Madrigals MASH drug launch gets off to a fast start (BioPharma Dive)
Aug-05-24 06:30AM	Is It Too Late to Buy Madrigal Pharmaceuticals Stock? (Motley Fool) -5.78%
Aug-02-24 07:00AM	Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel (GlobeNewswire)
Jul-24-24 08:00AM	Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
Jun-30-24 12:02PM	Is Madrigal Pharmaceuticals a Millionaire Maker? (Motley Fool)
Jun-28-24 06:45AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
Jun-16-24 12:05PM	Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. (Motley Fool)
Jun-15-24 09:45AM	Where Will Madrigal Pharmaceuticals Be in 3 Years? (Motley Fool)
Jun-12-24 03:56PM	Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
Jun-10-24 09:45AM	Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
Jun-06-24 08:00AM	Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress (GlobeNewswire)
Jun-05-24 04:10PM	Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
03:17PM	What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? (Benzinga)
10:56AM	Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
08:00AM	Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-29-24 08:00AM	Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress (GlobeNewswire)
May-24-24 03:17AM	Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ... (GuruFocus.com)
May-21-24 09:45AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
May-17-24 03:08AM	Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing (MT Newswires)
May-15-24 09:19PM	John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role (GuruFocus.com)
May-10-24 08:51AM	B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating (MT Newswires)
May-09-24 10:53AM	UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating (MT Newswires)
May-08-24 01:23PM	Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:02AM	Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CRAVES FRED B	Director	Mar 12 '25	Option Exercise	100.77	7,728	778,784	357,804	Mar 14 04:25 PM
CRAVES FRED B	Director	Mar 13 '25	Option Exercise	65.06	7,742	503,695	357,818	Mar 14 04:25 PM
CRAVES FRED B	Director	Mar 12 '25	Sale	331.84	7,728	2,564,426	350,076	Mar 14 04:25 PM
CRAVES FRED B	Director	Mar 13 '25	Sale	325.25	7,742	2,518,053	350,076	Mar 14 04:25 PM
FRED CRAVES	Director	Mar 13 '25	Proposed Sale	325.25	7,742	2,518,054		Mar 13 05:03 PM
Dier Mardi	SVP and CFO	Mar 10 '25	Sale	323.04	258	83,344	10,440	Mar 12 04:32 PM
FRED CRAVES	Director	Mar 12 '25	Proposed Sale	331.92	7,428	2,465,514		Mar 12 04:11 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 05 '25	Option Exercise	87.49	14,113	1,234,766	17,841	Mar 07 05:40 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 05 '25	Sale	341.32	14,113	4,817,104	3,728	Mar 07 05:40 PM
Kelley Shannon T	General Counsel	Mar 03 '25	Sale	335.00	415	139,025	7,290	Mar 05 04:36 PM
Dier Mardi	SVP and CFO	Mar 03 '25	Sale	324.96	1,961	637,248	6,914	Mar 05 04:31 PM
Huntsman Carole	Chief Commercial Officer	Mar 03 '25	Sale	325.98	1,834	597,840	8,604	Mar 05 04:24 PM
ROBERT WALTERMIRE	Officer	Mar 05 '25	Proposed Sale	341.32	14,113	4,817,104		Mar 05 04:07 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Feb 28 '25	Sale	341.07	1,227	418,488	3,728	Mar 04 09:24 PM
Mardi Dier	Officer	Mar 03 '25	Proposed Sale	325.89	1,187	386,834		Mar 03 08:27 PM
SHANNON KELLEY	Officer	Mar 03 '25	Proposed Sale	341.27	415	141,627		Mar 03 04:51 PM
CAROLE A HUNTSMAN	Officer	Mar 03 '25	Proposed Sale	341.27	1,834	625,889		Mar 03 04:12 PM
ROBERT WALTERMIRE	Officer	Feb 28 '25	Proposed Sale	341.07	1,227	418,488		Feb 28 04:59 PM
Daly James M	Director	Feb 27 '25	Option Exercise	82.90	15,470	1,282,478	17,382	Feb 28 04:31 PM
Daly James M	Director	Feb 27 '25	Sale	347.45	15,470	5,375,126	1,912	Feb 28 04:31 PM
BATE KENNETH	Director	Feb 27 '25	Option Exercise	66.26	20,000	1,325,287	21,912	Feb 28 04:30 PM
BATE KENNETH	Director	Feb 27 '25	Sale	356.44	20,000	7,128,759	1,912	Feb 28 04:30 PM
JAMES M DALY	Director	Feb 27 '25	Proposed Sale	347.45	15,470	5,375,126		Feb 27 04:54 PM
KENNETH M BATE	Director	Feb 27 '25	Proposed Sale	356.44	20,000	7,128,758		Feb 27 04:51 PM
Huntsman Carole	Chief Commercial Officer	Jan 24 '25	Sale	335.24	347	116,328	10,438	Jan 27 05:18 PM
Sibold William John	President and CEO	Jan 24 '25	Sale	335.24	1,584	531,020	54,303	Jan 27 05:12 PM
Taub Rebecca	Pres., R&D, and CMO	Jan 24 '25	Sale	335.24	648	217,236	456,662	Jan 27 05:07 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jan 24 '25	Sale	335.24	103	34,530	4,955	Jan 27 05:03 PM
Rebecca Taub	Officer	Jan 24 '25	Proposed Sale	340.14	648	220,411		Jan 24 06:00 PM
William John Sibold	Officer	Jan 24 '25	Proposed Sale	340.14	1,584	538,782		Jan 24 06:00 PM
Carole Huntsman	Officer	Jan 24 '25	Proposed Sale	340.14	347	118,029		Jan 24 06:00 PM
Robert E Waltermire	Officer	Jan 24 '25	Proposed Sale	340.14	103	35,034		Jan 24 06:00 PM
Kelley Shannon T	General Counsel	Jan 17 '25	Sale	273.41	277	75,735	7,705	Jan 17 07:10 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jan 17 '25	Sale	273.41	442	120,847	5,058	Jan 17 07:08 PM
Taub Rebecca	Pres., R&D, and CMO	Jan 17 '25	Sale	273.41	1,689	461,789	457,310	Jan 17 07:05 PM
Rebecca Taub	Officer	Jan 17 '25	Proposed Sale	272.79	1,689	460,742		Jan 17 05:30 PM
Shannon Kelley	Officer	Jan 17 '25	Proposed Sale	272.79	277	75,563		Jan 17 05:30 PM
Robert E Waltermire	Officer	Jan 17 '25	Proposed Sale	272.79	442	120,573		Jan 17 05:30 PM
CRAVES FRED B	Director	Dec 03 '24	Sale	315.31	3,600	1,135,122	11,000	Dec 05 04:46 PM
CRAVES FRED B	Director	Nov 25 '24	Sale	350.30	3,400	1,191,028	14,600	Nov 27 04:16 PM
CRAVES FRED B	Director	Nov 25 '24	Proposed Sale	322.73	10,000	3,227,300		Nov 25 04:10 PM
Huntsman Carole	Chief Commercial Officer	Nov 21 '24	Sale	316.92	688	218,041	10,785	Nov 22 04:30 PM
Carole Huntsman	Officer	Nov 21 '24	Proposed Sale	316.92	688	218,040		Nov 21 04:30 PM
Levy Richard S	Director	Nov 07 '24	Option Exercise	7.36	5,000	36,800	16,012	Nov 08 05:07 PM
Levy Richard S	Director	Nov 07 '24	Sale	350.00	5,000	1,750,000	11,012	Nov 08 05:07 PM
RICHARD S LEVY	Director	Nov 07 '24	Proposed Sale	338.22	5,000	1,691,100		Nov 07 04:36 PM
Levy Richard S	Director	Nov 01 '24	Option Exercise	7.36	5,000	36,800	16,012	Nov 05 07:01 PM
Levy Richard S	Director	Nov 01 '24	Sale	300.94	5,000	1,504,703	11,012	Nov 05 07:01 PM
RICHARD S LEVY	Director	Nov 01 '24	Proposed Sale	259.34	5,000	1,296,700		Nov 01 04:47 PM
Sibold William John	President and CEO	Sep 09 '24	Sale	243.83	6,363	1,551,490	55,887	Sep 11 09:51 PM
William John Sibold	Officer	Sep 09 '24	Proposed Sale	243.83	6,363	1,551,514		Sep 10 09:29 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Option Exercise	87.09	1,900	165,471	7,400	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Sale	280.00	1,900	532,000	5,500	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Option Exercise	87.92	2,000	175,840	7,500	Jun 14 09:44 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Sale	285.00	2,000	570,000	5,500	Jun 14 09:44 PM

TARA

Protara Therapeutics Inc

MDGL

Madrigal Pharmaceuticals Inc

Upgrade your FINVIZ experience